Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Filings indexed 1,091 across all filing types
Latest filing 2010-05-07 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2010-05-07 English
4 Filing
Director's Dealing
2010-05-07 English
4 Filing
Director's Dealing
2010-05-07 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content details a material definitive agreement related to the issuance and sale of preferred stock and warrants, including financing terms and related agreements. It also discusses creation of financial obligations and unregistered sales of equity securities. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, proxy, or governance document. It primarily provides an update on financing activities and securities issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7,672 characters) and detailed content support this classification with high confidence.
2010-05-04 English
4 Filing
Director's Dealing
2010-04-29 English
SC 13D/A Filing
Major Shareholding Notification
2010-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.